---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-296936"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-07-07T12:15:15+00:00"
generated_at: "2026-07-07T12:20:06.264041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Breakthrough T1D awards grant for SAB-142 study in Stage 3 T1D beyond 100 days

## Summary
- Breakthrough T1D awarded grant to Dr. Michael Haller (U. Florida) for PRISE-hATG study of SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.
- Study aims to assess SAB-142's ability to preserve C-peptide and modulate immune responses in patients with residual beta cell function beyond 100 days.
- SAB BIO will co-fund the study; it complements ongoing Phase 2b SAFEGUARD trial in new onset Stage 3 T1D.
- CEO Samuel Reich says SAB-142 has potential as best-in-class disease-modifying therapy for T1D.

## SEC filing metadata
- accession: 0001193125-26-296936
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-07-07T12:15:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/0001193125-26-296936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/sabs-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-296936
- JSON: https://secwatch.observer/filing/0001193125-26-296936.json
- Plain text: https://secwatch.observer/filing/0001193125-26-296936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.